1RO Validation of a prognostic circulating immune protein signature and exploratory dynamic biomarker analyses from the phase III ANITA (ENGOT-Ov41/GEICO 69-O) trial in recurrent ovarian cancer (OC)

A. González-Martín; B. Tavira; J. González-Gomariz; MJ Rubio Pérez; I.L. Ray-Coquard; F. Heitz; T. van Gorp; V. Zizioli; A. Oaknin; A. Leary; P Wimberger; L. Gaba Garcia; C. Lebreton; A.M. Santaballa Bertran; M.J. Bermejo‐Pérez; L.M. De Sande González; A. Redondo; M.P. Barretina Ginesta; F. Kridelka; R. Armananzas

doi:10.1016/j.esmoop.2026.108026

Key Points

This research aims to validate a prognostic signature of circulating immune proteins for predicting overall survival in recurrent ovarian cancer.
Validation of a previously developed signature involving circulating immune-oncology proteins and clinical variables.
Exploratory longitudinal analyses conducted using data from the phase III ANITA trial.
Combination of 4 baseline circulating immune proteins and 4 clinical variables.
Validation confirms the effectiveness of the immune protein signature in predicting overall survival.
Longitudinal analyses provide insights into the dynamic behavior of biomarkers over time.

Implication

Validates a protein signature predicting overall survival in recurrent ovarian cancer, suggesting improved patient management.

Abstract

Previously we developed a signature combining 4 baseline (BL) circulating immune-oncology proteins and 4 clinical variables to predict overall survival (OS) in ANITA [ESMO 2025]. Here we report signature validation and exploratory longitudinal analyses.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

González-Martín et al. (2026) studied this question.

synapsesocial.com/papers/6a48a78b89561a0c2d78eda7 https://doi.org/10.1016/j.esmoop.2026.108026

View Full Paper

Ask AI

Bookmark

Share

1RO Validation of a prognostic circulating immune protein signature and exploratory dynamic biomarker analyses from the phase III ANITA (ENGOT-Ov41/GEICO 69-O) trial in recurrent ovarian cancer (OC)

Key Points

Implication

Abstract

Discussion

Cite This Study

1RO Validation of a prognostic circulating immune protein signature and exploratory dynamic biomarker analyses from the phase III ANITA (ENGOT-Ov41/GEICO 69-O) trial in recurrent ovarian cancer (OC)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading